STVN — Stevanato Group S.p.A. stock price, charts and financials

NYSE·Healthcare·Medical - Instruments & Supplies·IT

Latest market price

19.65

-0.94-4.57%

Overview Short InterestFilings

STVNQT48Stevanato Group S.p.A.·NYSE

Overview Short InterestFilings

19.65-4.57%

News

Down 4.6% — Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MMSI+0.34%$85.82 BLCO-0.54%$16.68 TFX+0.30%$140.12 NVST+2.16%$27.96 ICUI-0.57%$171.96 RGEN+1.85%$149.78 ATR-0.43%$136.18 AVTR+0.07%$13.68

Snapshot

Index	-	P/E	33.31	EPS (ttm)	0.59	Insider Own	0.24%	Shs Outstand	273.00M	Perf Week	-2.48%

Market Cap	5.36B	Forward P/E	23.50	EPS next Y	0.84	Insider Trans	-0.90%	Shs Float	273.00M	Perf Month	1.92%

Enterprise Value	5.75B	PEG	1.72	EPS next Q	-	Inst Own	-	Short Float	0.35%	Perf Quarter	10.46%

Income	164.00M	P/S	3.86	EPS this Y	18.93%	Inst Trans	-	Short Ratio	2.36	Perf Half Y	24.92%

Sales	1.39B	P/B	3.03	EPS next Y	19.16%	ROA	5.46%	Short Interest	966.43K	Perf YTD	-2.34%

Book/sh	6.48	P/C	41.26	EPS next 5Y	19.40%	ROE	9.63%	52W High	28.00 -29.82%	Perf Year	-21.78%

Cash/sh	0.48	P/FCF	-	EPS past 3/5Y	-0.27% 11.60%	ROIC	6.77%	52W Low	12.89 52.44%	Perf 3Y	-36.96%

Dividend Est.	0.06 (0.32%)	EV/EBITDA	16.80	Sales past 3/5Y	7.51% 11.22%	Gross Margin	29.01%	Volatility	5.22% 4.30%	Perf 5Y	-1.26%

Dividend TTM	0.06 (0.32%)	EV/Sales	4.13	EPS Y/Y TTM	26.82%	Oper. Margin	16.57%	ATR (14)	0.90	Perf 10Y	-

Dividend Ex-Date	Jun 11, 2026	Quick Ratio	1.11	Sales Y/Y TTM	16.50%	Profit Margin	11.75%	RSI (14)	52.66	Recom	2.38

Dividend Gr. 3/5Y	6.61% -	Current Ratio	1.63	EPS Q/Q	18.18%	SMA20	-0.20%	Beta	0.70	Target Price	24.75

Payout	0.04%	Debt/Eq	0.32	Sales Q/Q	18.52%	SMA50	5.34%	Rel Volume	2.73	Prev Close	20.59

Employees	6,010	LT Debt/Eq	0.23	Earnings	Nov 05	SMA200	4.97%	Avg Volume	374.42K	Price	19.65

IPO Date	Jul 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.11% 0.11%	Net Debt/EBITDA	1.14	Volume	1,022,963	Change	-4.57%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-05-26	Reiterated	Keybanc	Overweight	$32
Feb-10-26	Reiterated	Jefferies	Hold	$23 → $18
Aug-07-24	Reiterated	Citigroup	Buy	$28
Nov-01-23	Downgrade	Jefferies	Buy → Hold
Sep-26-23	Reiterated	Stephens		$33
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal Weight
Jan-06-23	Reiterated	Morgan Stanley	Overweight	$22
Apr-25-22	Reiterated	Wells Fargo	Overweight	$19

Latest News

Aug-04-26

Aug-04-2603:20PM

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcriptseekingalpha.com

08:51AM

Stevanato Group (STVN) Q2 Earnings Top Estimateszacks.com

06:30AM

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026businesswire.com

Jul-30-26

Jul-30-2606:38AM

Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In EuropeBenzinga

06:30AM

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countriesbusinesswire.com

Jul-21-26

Jul-21-2606:30AM

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026businesswire.com

Jun-16-26

Jun-16-2609:56PM

TD Cowen Initiates Coverage of Stevanato Group S.p.A. (STVN) with Buy RecommendationFintel

01:02PM

TD Cowen Initiates Coverage On Stevanato Group with Buy Rating, Announces Price Target of $25Benzinga

Jun-11-26

Jun-11-2602:54AM

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling UpsideSeekingAlpha

Company

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	1,391	1,285	1,194	1,174	1,034	998	755	601
Cost of Goods Sold Incl. D&A	987	913	867	806	698	684	534	446
Gross Profit	403	373	327	368	336	314	221	155
Selling, General and Administrative Excl. Other	147	139	128	123	118	98	90	86
Research and Development	30	28	34	39	36	35	20	9
Other Operating Expense	-4	-1	-9	-11	-20	-11	-6	-10
Operating Income	231	207	174	217	202	192	118	70
Interest Expense	10	25	7	5	4	6	8	6
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	3	23	7	-7	-1	10	0	-2
Net Income Before Taxes	223	205	173	205	197	196	110	61
Income Taxes	60	53	46	47	47	37	20	18
Consolidated Net Income	164	151	127	158	150	159	90	44
Net Income From Continuing Operations	164	151	127	158	150	159	90	43
Net Income	164	151	127	158	150	159	90	44
EPS (Recurring)	0.59	0.55	0.47	0.59	0.56	0.63	0.32	0.17
EPS (Basic, Before Extraordinaries)	0.59	0.55	0.47	0.59	0.56	0.63	0.32	0.17
EPS (Diluted)	0.59	0.55	0.47	0.59	0.56	0.63	0.32	0.17
EBITDA	342	326	268	295	270	268	178	119
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	33.31	36.40	46.84	45.87	32.24	35.82	—	—
Price To Sales Ratio	3.86	4.27	4.98	6.16	4.61	5.96	—	—
Gross Margin	28.97	29.03	27.39	31.35	32.50	31.46	29.27	25.79
Operating Margin	16.61	16.11	14.57	18.48	19.54	19.24	15.63	11.65
Net Margin	11.79	11.75	10.64	13.46	14.51	15.93	11.92	7.32
Shares Outstanding	273	273	273	265	265	265	265	265
Market Capitalization	5,364	5,493	5,949	7,232	4,762	5,949	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Balachandran Madhavan	Director	Jun 15 '26	Sale	17.09	1,493	25,515	69,458	Jun 26
MOREL DONALD E JR	Director	Jun 15 '26	Sale	17.09	1,493	25,515	37,424	Jun 26
FEDERICI WILLIAM J	Director	Jun 15 '26	Sale	17.09	1,493	25,515	26,991	Jun 26
Flynn Karen	Director	Jun 15 '26	Sale	17.09	1,493	25,515	5,757	Jun 26
Dal Lago Marco	Chief Financial Officer	Jun 12 '26	Option Exercise	0.00	15,994	0	85,353	Jun 26
Stocchi Mauro	See Remarks	Jun 09 '26	Option Exercise	0.00	13,172	0	413,629	Jun 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.